Inserm UMR-S1140, Paris, France.
Sorbonne Paris Cite, Université Paris Descartes, Paris, France.
Stem Cell Rev Rep. 2018 Apr;14(2):223-235. doi: 10.1007/s12015-017-9778-5.
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by obliteration of alveolar architecture, resulting in declining lung function and ultimately death. Pathogenic mechanisms remain unclear but involve a concomitant accumulation of scar tissue together with myofibroblasts activation. Microparticles (MPs) have been investigated in several human lung diseases as possible pathogenic elements, prognosis markers and therapeutic targets. We postulated that levels and cellular origins of circulating MPs might serve as biomarkers in IPF patients and/or as active players of fibrogenesis. Flow cytometry analysis showed a higher level of Annexin-V positive endothelial and platelet MPs in 41 IPF patients compared to 22 healthy volunteers. Moreover, in IPF patients with a low diffusing capacity of the lung for carbon monoxide (DL<40%), endothelial MPs (EMPs) were found significantly higher compared to those with DL>40% (p = 0.02). We then used EMPs isolated from endothelial progenitor cells (ECFCs) extracted from IPF patients or controls to modulate normal human lung fibroblast (NHLF) properties. We showed that EMPs did not modify proliferation, collagen deposition and myofibroblast transdifferentiation. However, EMPs from IPF patients stimulated migration capacity of NHLF. We hypothesized that this effect could result from EMPs fibrinolytic properties and found indeed higher plasminogen activation potential in total circulating MPs and ECFCs derived MPs issued from IPF patients compared to those isolated from healthy controls MPs. Our study showed that IPF is associated with an increased level of EMPs in the most severe patients, highlighting an active process of endothelial activation in the latter. Endothelial microparticles might contribute to the lung fibroblast invasion mediated, at least in part, by a fibrinolytic activity.
特发性肺纤维化(IPF)是一种破坏性疾病,其特征是肺泡结构破坏,导致肺功能下降,最终导致死亡。发病机制尚不清楚,但涉及到瘢痕组织的同时积累以及肌成纤维细胞的激活。微颗粒(MPs)已在几种人类肺部疾病中进行了研究,作为可能的致病因素、预后标志物和治疗靶点。我们假设循环 MPs 的水平和细胞起源可能作为 IPF 患者的生物标志物和/或作为纤维化发生的活性参与者。流式细胞术分析显示,与 22 名健康志愿者相比,41 名 IPF 患者中 Annexin-V 阳性内皮和血小板 MPs 的水平更高。此外,在弥散量低于 40%的 IPF 患者中,内皮 MPs(EMPs)明显高于弥散量大于 40%的患者(p=0.02)。然后,我们使用从 IPF 患者或对照者中提取的内皮祖细胞(ECFCs)分离的 EMPs 来调节正常的人肺成纤维细胞(NHLF)特性。我们发现 EMPs 不会改变增殖、胶原蛋白沉积和肌成纤维细胞的转分化。然而,来自 IPF 患者的 EMPs 刺激了 NHLF 的迁移能力。我们假设这种作用可能是由于 EMPs 的纤溶特性所致,并且实际上在总循环 MPs 和源自 IPF 患者的 ECFCs 衍生的 MPs 中发现了更高的纤溶酶原激活潜力,而与从健康对照者中分离的 MPs 相比。我们的研究表明,在最严重的患者中,IPF 与 EMPs 水平升高有关,这突出了后者内皮激活的活跃过程。内皮微颗粒可能有助于至少部分由纤溶活性介导的肺成纤维细胞浸润。